CurrentFlorida BluePolicy N/A

GLP-1 drug class coverage (commercial & Medicare pharmacy)

Defines Florida Blue pharmacy coverage and prior authorization requirements for GLP-1 class medications for commercial and Medicare members; affects prescribers and authorization request workflows.

Policy Summary

PayerFlorida Blue

PolicyGLP-1 drug class coverage (commercial & Medicare pharmacy)

Policy CodePolicy N/A

Change TypeCoverage criteria revisedproduct exclusion added

Effective DateApril 1, 2024

Next Review Date

Key ActionInclude clinical documentation of type 2 diabetes diagnosis and evidence of trial/failure of metformin (or combinations) or insulin with prior authorization requests.

SourceLink

POLICY UPDATE CHANGES

Commercial prior authorization criteria updated to require clinical documentation of type 2 diabetes diagnosis and documentation of trial/failure of metformin, metformin combinations, or insulin.

Victoza excluded from coverage for commercial plans effective April 1, 2024 (continued coverage allowed until July 1, 2024 for current members).

Medicare and Florida Blue plans do not cover GLP-1 medications when requested for weight loss/management and such requests will be denied.

2024-04-01Victoza exclusion

2024-07-01Continuation until

5Preferred GLP-1 count

Coverage Criteria for GLP-1 Medications

Initial Therapy (Commercial)

Covered for commercial plans when ALL of the following are met:

Commercial GLP-1 coverage for type 2 diabetes: Member has a documented diagnosis of type 2 diabetes and clinical documentation is submitted with the prior authorization request.

Applies to FDA‑approved GLP-1 indications only; Victoza is excluded from commercial coverage effective 2024-04-01 (current commercial members on Victoza may continue until 2024-07-01).

Prior therapy requirement: Documentation shows the patient has tried and failed (or is intolerant to) metformin, metformin combination drugs, or insulin.

This trial/failure documentation must be included in the prior authorization submission to demonstrate medical necessity.

Medicare

Medicare coverage for GLP-1:

Policy Summary

PayerFlorida Blue

PolicyGLP-1 drug class coverage (commercial & Medicare pharmacy)

Policy CodePolicy N/A

Change TypeCoverage criteria revisedproduct exclusion added

Effective DateApril 1, 2024

Next Review Date

Key ActionInclude clinical documentation of type 2 diabetes diagnosis and evidence of trial/failure of metformin (or combinations) or insulin with prior authorization requests.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medicare GLP-1 coverage: Covered for FDA‑approved indications related to treatment of type 2 diabetes when requirements of the Medicare plan and myPrime prior authorization processes are met.

Medicare and Florida Blue exclude GLP-1 medications when prescribed for weight loss/management; Victoza remains listed as covered for Medicare per the provider list.

Medicare and Florida Blue plans exclude coverage of GLP-1 medications when prescribed for weight loss or weight management. Examples include agents commonly used for obesity management such as Wegovy and Saxenda. Prior authorization requests submitted for a weight-loss/management indication will be denied; providers should inform patients that these drugs will not be covered and must be paid for out-of-pocket if pursued.

Operationally, to avoid denials do not submit prior authorization requests to Prime Therapeutics (or via myPrime) for GLP-1 medications when the indication is weight loss/management. Submitting such requests will result in denial and creates unnecessary administrative burden.

Requests for GLP-1 drugs for off-label indications — including use for weight loss/management — are considered not covered and will be denied. Florida Blue and Medicare do not approve prior authorization requests for off-label indications for this drug class.

If a prescriber believes a GLP-1 is appropriate for weight management, do not submit a prior authorization request through Prime Therapeutics or myPrime; instead inform the patient that the medication is not covered and would be an out-of-pocket expense.

Provider Actions and Prior Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for GLP-1 drugs. For Florida Blue commercial plans, prior authorization will only be approved for FDA‑approved indications related to treatment of type 2 diabetes. Requests for off‑label indications (including weight loss/management agents such as Wegovy or Saxenda) will be denied.

Applies to Florida Blue commercial plans
Medicare follows federal exclusions for weight‑loss indications

Step Therapy

Step Therapy Requirement

Providers must document failure or intolerance to metformin, metformin combination products, or insulin before a GLP-1 prior authorization will be approved. Evidence of prior trial and reason for discontinuation (e.g., adverse effects, inadequate response) should be included in the clinical record submitted with the request.

Document trial of metformin, metformin combination drugs, or insulin
Include reason for failure or intolerance

Documentation Required

Required Clinical Documentation

When submitting a prior authorization request, include clinical documentation from the patient’s medical record showing a diagnosis of type 2 diabetes and documentation that prior therapy requirements have been met. For members currently on Victoza under commercial plans, include supporting records to continue coverage where applicable.

Clinical notes confirming type 2 diabetes diagnosis
Records showing prior trials of metformin/metformin combinations or insulin
For Victoza (commercial): documentation supporting continued therapy through July 1, 2024 where applicable

Denial Risk

Denial Triggers

Authorization requests that do not include clinical documentation of a type 2 diabetes diagnosis or evidence of prior trial/failure/intolerance to metformin, metformin combination drugs, or insulin will be denied. Requests for GLP-1s for weight loss/management or other non‑FDA‑approved indications will be denied.

Missing type 2 diabetes diagnosis documentation triggers denial
Missing prior therapy documentation triggers denial
Requests for weight‑loss indications (e.g., Wegovy, Saxenda) will be denied

Initial Authorization Criteria

Initial Authorization

Initial authorization requirements (commercial):

Prior therapy documentation: Include documentation that the patient has tried and failed (or is intolerant to) metformin, metformin combination drugs, or insulin.

This information must be present in the prior authorization request to establish medical necessity for GLP-1 therapy.

Indication limitation: Request is for an FDA‑approved indication for type 2 diabetes only.

Requests for off-label indications, including weight loss/management, will be denied.

Continuation (Renewal) Criteria

Continuation

Continuation for existing members

Victoza continuation (commercial): Current commercial members receiving Victoza are allowed continued coverage until July 1, 2024 despite the commercial exclusion effective April 1, 2024.

After July 1, 2024 commercial coverage for Victoza will cease; Medicare coverage for Victoza remains per provider list.

Step Therapy Requirements

Step	Requirement (must be shown in submitted medical records)
1	Documentation of a diagnosis of type 2 diabetes in the patient’s medical record
	Clinical records showing trial and failure or intolerance to metformin, metformin combination drugs, or insulin (must be submitted with the prior authorization request)
	For commercial plans only: note that Victoza is excluded effective April 1, 2024; current members on Victoza may continue coverage until July 1, 2024 — include documentation of member’s current therapy if applicable
	Requests for GLP-1 medications for weight loss/management (e.g., Wegovy, Saxenda) are excluded and will be denied — do not submit as an indication for approval

Definitions

GLP-1 drug class — definitions and scope

Drug class termGlucagon-like Peptide 1 (GLP-1) medications used for glycemic control in type 2 diabetes

Included drug names (from policy)Mounjaro; Ozempic; Rybelsus; Trulicity; Victoza; Wegovy; Saxenda

Indication coveredFDA‑approved indications related to treatment of type 2 diabetes

Indication excludedWeight loss/management indications (e.g., Wegovy, Saxenda) — not covered and will be denied

Prior authorization requirementPrior authorization is required; commercial approvals only for FDA‑approved diabetes indications when required documentation is provided

Background

Glucagon-like peptide-1 (GLP-1) receptor agonists are FDA‑approved treatments for type 2 diabetes but have attracted off-label use for weight loss. Florida Blue limits coverage to FDA‑approved indications related to type 2 diabetes and requires supporting clinical documentation with prior authorization requests to demonstrate medical necessity.

For commercial plans the policy requires providers to submit clinical documentation of a type 2 diabetes diagnosis and evidence that the member has tried and failed (or is intolerant to) metformin, metformin combination drugs, or insulin before a GLP-1 will be approved. The policy also notes that Victoza is excluded from commercial coverage effective April 1, 2024 with continuation for current members only through July 1, 2024.